company background image
1672

Ascletis Pharma SEHK:1672 Stock Report

Last Price

HK$2.56

Market Cap

HK$2.8b

7D

-7.9%

1Y

0.4%

Updated

04 Oct, 2022

Data

Company Financials +
1672 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

1672 Stock Overview

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally.

Ascletis Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ascletis Pharma
Historical stock prices
Current Share PriceHK$2.56
52 Week HighHK$7.26
52 Week LowHK$2.49
Beta0.57
1 Month Change-17.69%
3 Month Change-38.16%
1 Year Change0.39%
3 Year Change-17.15%
5 Year Changen/a
Change since IPO-81.71%

Recent News & Updates

Aug 24
Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Market forces rained on the parade of Ascletis Pharma Inc. ( HKG:1672 ) shareholders today, when the analysts...

Shareholder Returns

1672HK BiotechsHK Market
7D-7.9%-5.4%-4.5%
1Y0.4%-58.8%-28.6%

Return vs Industry: 1672 exceeded the Hong Kong Biotechs industry which returned -59.2% over the past year.

Return vs Market: 1672 exceeded the Hong Kong Market which returned -28.3% over the past year.

Price Volatility

Is 1672's price volatile compared to industry and market?
1672 volatility
1672 Average Weekly Movement6.4%
Biotechs Industry Average Movement8.2%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.7%
10% least volatile stocks in HK Market3.2%

Stable Share Price: 1672 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 1672's weekly volatility has decreased from 12% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013315Jinzi Jason Wuhttps://www.ascletis.com

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.

Ascletis Pharma Inc. Fundamentals Summary

How do Ascletis Pharma's earnings and revenue compare to its market cap?
1672 fundamental statistics
Market CapHK$2.78b
Earnings (TTM)-HK$194.41m
Revenue (TTM)HK$86.67m

32.1x

P/S Ratio

-14.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1672 income statement (TTM)
RevenueCN¥78.55m
Cost of RevenueCN¥12.45m
Gross ProfitCN¥66.10m
Other ExpensesCN¥242.29m
Earnings-CN¥176.19m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin84.16%
Net Profit Margin-224.31%
Debt/Equity Ratio0%

How did 1672 perform over the long term?

See historical performance and comparison